KANJINTI
Drug timelines are a Plus or Pro feature.
5 regulatory and trial events tracked for KANJINTI, covering 2019-06-13 to 2026-08-11. Get the full timeline:
Most recent: EMA Authorised: Kanjinti (trastuzumab) — Amgen Europe B.V.
5 regulatory and trial events tracked for KANJINTI, covering 2019-06-13 to 2026-08-11. Get the full timeline:
Most recent: EMA Authorised: Kanjinti (trastuzumab) — Amgen Europe B.V.